Literature DB >> 21174069

[PSP Scale: German version of the Personal and Social Performance Scale: valid instrument for the assessment of psychosocial functioning in the treatment of schizophrenia].

D Schaub1, G Juckel.   

Abstract

In the treatment of schizophrenia, the domain of psychosocial functioning is an important aspect of therapeutic success that should be considered in addition to the reduction of psychopathology. Valid and standardised measures are necessary for diagnostics and the assessment of patients" personal, social and professional functioning. The German version of the Personal and Social Performance (PSP) Scale (with its four subdimensions: "socially useful activities, work and study included", "personal and social relationships", "self-care" and "disturbing and aggressive behaviour") was administered to patients with schizophrenia in previous studies. These data demonstrated this scale to be a reliable, valid and efficient tool for measuring psychosocial functioning in schizophrenia. Thus, it is argued that, for everyday clinical practice, the PSP Scale is useful for the assessment of psychosocial functioning in schizophrenia during short, medium and long-term treatment courses.

Entities:  

Mesh:

Year:  2011        PMID: 21174069     DOI: 10.1007/s00115-010-3204-4

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  13 in total

1.  [Quality of life--what it means to me... Results of a survey among schizophrenic patients].

Authors:  M C Angermeyer; A Holzinger; H Matschinger
Journal:  Psychiatr Prax       Date:  1999-03

2.  Social skills and behavioral problems in schizophrenia: the role of mental state attribution, neurocognition and clinical symptomatology.

Authors:  Martin Brüne; Daniela Schaub; Georg Juckel; Robyn Langdon
Journal:  Psychiatry Res       Date:  2010-04-24       Impact factor: 3.222

3.  [For and against: is quality of life a meaningful indicator of outcome? For].

Authors:  Reinhold Kilian
Journal:  Psychiatr Prax       Date:  2006-10

Review 4.  Social functioning as an outcome measure in schizophrenia studies.

Authors:  T Burns; D Patrick
Journal:  Acta Psychiatr Scand       Date:  2007-10-17       Impact factor: 6.392

5.  Optimizing treatment of schizophrenia. Enhancing affective/cognitive and depressive functioning.

Authors:  David L Ginsberg; Nina R Schooler; Peter F Buckley; Philip D Harvey; Peter J Weiden
Journal:  CNS Spectr       Date:  2005-02       Impact factor: 3.790

6.  [The "Mini-ICF-Rating for Mental Disorders (Mini-ICF-P)". A short instrument for the assessment of disabilities in mental disorders].

Authors:  M Linden; S Baron
Journal:  Rehabilitation (Stuttg)       Date:  2005-06       Impact factor: 1.113

7.  Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning.

Authors:  P L Morosini; L Magliano; L Brambilla; S Ugolini; R Pioli
Journal:  Acta Psychiatr Scand       Date:  2000-04       Impact factor: 6.392

8.  Is theory of mind in schizophrenia more strongly associated with clinical and social functioning than with neurocognitive deficits?

Authors:  Rita Roncone; Ian R H Falloon; Monica Mazza; Alessandro De Risio; Rocco Pollice; Stefano Necozione; PierLuigi Morosini; Massimo Casacchia
Journal:  Psychopathology       Date:  2002 Sep-Oct       Impact factor: 1.944

Review 9.  Defining and measuring clinical effectiveness in the treatment of schizophrenia.

Authors:  Henry A Nasrallah; Steven D Targum; Rajiv Tandon; Jeffrey S McCombs; Ruth Ross
Journal:  Psychiatr Serv       Date:  2005-03       Impact factor: 3.084

10.  Validation of the Personal and Social Performance (PSP) Scale in a German sample of acutely ill patients with schizophrenia.

Authors:  Georg Juckel; Daniela Schaub; Nina Fuchs; Ute Naumann; Idun Uhl; Henning Witthaus; Ludger Hargarter; Hans-Werner Bierhoff; Martin Brüne
Journal:  Schizophr Res       Date:  2008-07-01       Impact factor: 4.939

View more
  5 in total

1.  [Disease and disability. The ICF model].

Authors:  M Linden
Journal:  Nervenarzt       Date:  2015-01       Impact factor: 1.214

2.  Transcutaneous noninvasive vagus nerve stimulation (tVNS) in the treatment of schizophrenia: a bicentric randomized controlled pilot study.

Authors:  Alkomiet Hasan; Claus Wolff-Menzler; Sebastian Pfeiffer; Peter Falkai; Elif Weidinger; Andrea Jobst; Imke Hoell; Berend Malchow; Peyman Yeganeh-Doost; Wolfgang Strube; Silke Quast; Norbert Müller; Thomas Wobrock
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-07-26       Impact factor: 5.270

3.  Apathy but not diminished expression in schizophrenia is associated with discounting of monetary rewards by physical effort.

Authors:  Matthias N Hartmann; Oliver M Hager; Anna V Reimann; Justin R Chumbley; Matthias Kirschner; Erich Seifritz; Philippe N Tobler; Stefan Kaiser
Journal:  Schizophr Bull       Date:  2014-07-22       Impact factor: 9.306

4.  [Psychiatric comorbidities in hidradenitis suppurativa/acne inversa].

Authors:  Paraskevi Mavrogiorgou; Georg Juckel; Andreas Reimelt; Schapoor Hessam; Lisa Scholl; Jessica Lisa Frajkur; Eggert Stockfleth; Falk G Bechara
Journal:  Hautarzt       Date:  2021-01-04       Impact factor: 0.751

5.  Aerobic endurance training to improve cognition and enhance recovery in schizophrenia: design and methodology of a multicenter randomized controlled trial.

Authors:  Andreas Meyer-Lindenberg; Peter Falkai; Isabel Maurus; Alkomiet Hasan; Andrea Schmitt; Astrid Roeh; Daniel Keeser; Berend Malchow; Thomas Schneider-Axmann; Martin Hellmich; Sabine Schmied; Moritz Lembeck; Katriona Keller-Varady; Irina Papazova; Dusan Hirjak; Cristina E Topor; Henrik Walter; Sebastian Mohnke; Bob O Vogel; Wolfgang Wölwer; Frank Schneider; Karsten Henkel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-08-03       Impact factor: 5.270

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.